MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ORKA had -$14,640K decrease in cash & cash equivalents over the period. -$88,419K in free cash flow.

Cash Flow Overview

Change in Cash
-$14,640K
Free Cash flow
-$88,419K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Proceeds from the pipe financing...
    • Accrued expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Related party accounts payable a...
    • Others

Cash Flow
2025-12-31
Net loss
-105,433
Stock-based compensation expense
24,240
Net accretion of premiums and discounts on marketable securities
5,003
Non-cash lease expense
458
Depreciation expense
83
Prepaid expenses and other current assets
3,972
Other non-current assets
60
Accounts payable
693
Accrued expenses and other current liabilities
7,245
Operating lease liability
-448
Related party accounts payable and other current liabilities
-6,013
Net cash used in operating activities
-88,210
Purchases of property and equipment
209
Purchases of marketable securities
520,959
Proceeds from maturities of marketable securities
424,423
Net cash used in investing activities
-96,745
Proceeds from the pipe financings, net
169,644
Proceeds from issuance of common stock upon exercise of stock options and employee warrants and purchases under employee stock purchase plan
671
Net cash provided by financing activities
170,315
Net (decrease) increase in cash and cash equivalents
-14,640
Cash and cash equivalents at beginning of period
61,575
Cash and cash equivalents at end of period
46,935
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from the pipefinancings, net$169,644K Proceeds from issuance ofcommon stock upon...$671K Net cash provided byfinancing activities$170,315K Net (decrease)increase in cash and cash...-$14,640K Canceled cashflow$170,315K Proceeds from maturitiesof marketable...$424,423K Stock-based compensationexpense$24,240K Accrued expenses andother current...$7,245K Accounts payable$693K Non-cash lease expense$458K Depreciation expense$83K Net cash used ininvesting activities-$96,745K Canceled cashflow$424,423K Net cash used inoperating activities-$88,210K Canceled cashflow$32,719K Purchases of marketablesecurities$520,959K Purchases of property andequipment$209K Net loss-$105,433K Related party accountspayable and other...-$6,013K Net accretion ofpremiums and discounts on...$5,003K Prepaid expenses andother current assets$3,972K Operating lease liability-$448K Other non-currentassets$60K

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA)